Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Both hormones bind to specific receptors on ovarian cells. Follicle‑stimulating hormone stimulates granulosa cells to proliferate and produce estradiol, while luteinising hormone triggers the final maturation of the dominant follicle and the ovulatory surge. Together they coordinate the growth and release of a mature egg.

The dose of Meriofert is individualized by the prescribing clinician based on the patient’s ovarian response, treatment protocol, and underlying condition. Dosage regimens are determined after careful monitoring of hormonal levels and ultrasound findings, and may be adjusted throughout the treatment cycle.

Meriofert is intended for use before conception to induce ovulation; its safety in established pregnancy has not been established, and it is generally not recommended during pregnancy. Limited data are available for breastfeeding, so clinicians usually advise against use while nursing until further information is obtained.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Meriofert combines both LH and FSH activities in a single injectable solution, whereas some alternatives provide only FSH or require separate LH supplementation. This dual‑action formulation can simplify dosing schedules and may improve follicular synchrony, but the choice of product depends on individual patient response and the specific protocol used by the fertility clinic.

Meriofert must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique when preparing the injection.

Meriofert is supplied as a sterile solution for injection and is administered either intramuscularly or subcutaneously, as directed by the treating physician. The injection is typically given in the abdomen or thigh, using a sterile needle and syringe, and the site should be rotated to reduce local irritation.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, rapid weight gain, and, in severe cases, fluid accumulation in the chest or abdomen. Multiple pregnancy and severe allergic reactions such as anaphylaxis are also rare but critical complications that require immediate medical attention.

Meriofert should be avoided in patients with active ovarian cysts, uncontrolled thyroid disease, known hypersensitivity to any component of the formulation, or those who have experienced severe OHSS in a previous cycle. It is also contraindicated in women who are currently pregnant.